Join STAT reporter Andrew Joseph for an online chat about the country’s first FDA-approved medication made from marijuana. He’ll take your questions about the future of marijuana regulation by states and the FDA, the potential rescheduling of cannabis and its components, and what makes the newly approved drug different from older medications that have components similar to those of marijuana.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Regarding the issue of pricing – doing a little math helps anchor the debate. GW Pharma’s trial showed you need A LOT of CBD to decrease seizure frequency.

    Typical 12-year old = 40 kg

    GW Pharma recommended dose = 10 mg / kg / day = 400 mg / day (this is 40x the amount of a typical THC dose [10mg])

    400 mg / day * 365 days / year = 146,000 mgs / year

    Typical CBD pricing from a dispensary = $0.12 / mg

    Total cost if you went to a dispensary instead of GW = $17,520 per year

    So, if GW Pharma goes with a pricing of $25,000 per year, their markup is relatively close to that of a typical dispensory. I’m sure their production costs are higher than the typical grow operations since it’s regulated by the FDA. I found the math surprising and it made the $25,000 – $50,000 per year number often quoted as a target price seem not as outragous.

  • A possible way to push the DEA would be a citizens lawsuit accusing the states of allowing easy access to minors of cannabis and cannabis product because of weak state laws, not hard to imagine in the present business environment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy